Sevgi B Rodan

20020040039, Apr 4, 2002

Sep 18, 2001

09/955379

George Hartman - Lansdale PA, US
Mark Duggan - Schwenksville PA, US
Gideon Rodan - Bryn Mawr PA, US
Sevgi Rodan - Bryn Mawr PA, US
Le Duong - Lansdale PA, US
Donald Kimmel - Doylestown PA, US

A61K031/443
A61K031/415
A61K031/365

514/336000, 514/406000, 514/473000

The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an , and/or integrin receptor antagonist in an amount effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compositions for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manufacture of a medicament useful in the treatment or prevention of an inflammatory disease or condition.

20040053968, Mar 18, 2004

Jul 1, 2003

10/250546

George Hartman - Lansdale PA, US
Sevgi Rodan - Bryn Mawr PA, US
Gideon Rodan - Bryn Mawr PA, US

A61K031/444
A61K031/365
A61K031/415
A61K031/42

514/333000, 514/406000, 514/473000, 514/378000

The present invention provides for a method for the treatment of alveolar bone loss due to periodontal disease in a subject in need of such treatment comprising administration of a therapeutically effective amount of an v3 integrin receptor antagonist in combination with a therapeutically effective amount of a COX-2 inhibitor. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating the alveolar bone loss due to periodontal disease.

20050004199, Jan 6, 2005

Sep 14, 2001

10/380785

George Hartman - Lansdale PA, US
Mark Duggan - Schwenksville PA, US
Gideon Rodan - Bryn Mawr PA, US
Sevgi Rodan - Bryn Mawr PA, US
Le Duong - Lansdale PA, US
Donald Kimmel - Doylestown PA, US

A61K031/415
A61K031/365

514406000, 514473000

The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an αβ, V5? and/or αβintegrin receptor antagonist in an amount effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compositions for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manufacture of a medicament useful in the treatment or prevention of an inflammatory disease or condition.

58561862, Jan 5, 1999

May 23, 1997

8/862556

Sevgi B. Rodan - Bryn Mawr PA
Gregg Wesolowski - Lansdale PA
Gideon A. Rodan - Bryn Mawr PA

Merck & Co., Inc. - Rahway NJ

C12N 500
C12N 502

435372

Methods of obtaining enriched populations of osteoclast precursor cells which can be released from tissue culture dishes and used for biochemical studies are described. Osteoblastic cells and bone marrow cells are co-cultured. Next a. alpha. sub. v. beta. sub. 3 receptor ligand, such as echistatin is used for cell detachment. The result is an 75-95% pure enriched population of tartrate resistant acid phosphatase (TRAP. sup. +) cells, in high yields (2-3. times. 10. sup. 6 cells per experiment) can be obtained. These cells are mostly mononucleated and based on their characteristics are considered to be pre-fusion osteoclasts (pOC cells). The precursor osteoclasts can be reseeded onto osteoblasts to obtain an enriched population of mature, multinucleated osteoclast cells.

57190585, Feb 17, 1998

Apr 10, 1995

8/419210

Sevgi B. Rodan - Bryn Mawr PA
Gregg Wesolowski - Lansdale PA
Gideon A. Rodan - Bryn Mawr PA

Merck & Co., Inc. - Rahway NJ

C12N 500

435372

Methods of obtaining enriched populations of osteoclast precursor cells which can be released from tissue culture dishes and used for biochemical studies are described. Osteoblastic cells and bone marrow cells are co-cultured. Next a. alpha. sub. v. beta. sub. 3 receptor ligand, such as echistatin is used for cell detachment. The result is an 75-95% pure enriched population of tartrate resistant acid phosphatase (TRAP. sup. +) cells, in high yields (2-3. times. 10. sup. 6 cells per experiment). These cells are mostly mononucleated and based on their characteristics are considered to be pre-fusion osteoclasts (pOC cells). The precursor osteoclasts can be reseeded onto osteoblasts to obtain an enriched population of mature, multinucleated osteoclast cells.

60935332, Jul 25, 2000

Nov 17, 1997

8/913988

Sevgi B. Rodan - Bryn Mawr PA
Gregg Wesolowski - Lansdale PA
Gideon A. Rodan - Bryn Mawr PA

Merck & Co., Inc. - Rahway NJ

C12Q 100
C12N 500
C12N 502

435 4

Methods of obtaining enriched populations of osteoclast precursor cells which can be released from tissue culture dishes and used for biochemical studies are described. Osteoblastic cells and bone marrow cells are co-cultured. Next a. alpha. sub. v. beta. sub. 3 receptor ligand, such as echistatin is used for cell detachment. The result is a 75-95% pure enriched population of tartrate resistant acid phosphatase (TRAP. sup. +) cells, in high yields (2-3. times. 10. sup. 6 cells per experiment) can be obtained. These cells are mosty mononucleated and based on their characteristics are considered to be pre-fusion osteoclasts (pOC cells). The precursor osteoclasts can be reseeded onto osteoblasts to obtain an enriched population of mature, multinucleated osteoclast cells.